Synapse - Oxford University Press

Oxford University Press

SHERPA: Yellow

People

Motzer
Scher
Rosenberg
Morris
Bajorin
Solit
Autio
Rathkopf
Iyer
Voss

Groups

Genitourinary Oncology Service (371)
Solid Tumor Oncology Division (371)
Department of Medicine (369)
GSK Faculty (44)
Epidemiology and Biostatistics (40)
Population Sciences Research Program (33)
Human Oncology and Pathogenesis Program (31)
Department of Pathology and Laboratory Medicine (30)
Survivorship Research (29)
Biostatistics Service (24)

Search Within

Results (371)

Export to EndNote / Excel

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Journal Article

Voss, M. H.; Hussain, A.; Vogelzang, N.; Lee, J. L.; Keam, B.; Rha, S. Y.; Vaishampayan, U.; Harris, W. B.; Richey, S.; Randall, J. M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Cora, N. S.; Sergio, B.; Ugo, D. G.; Giuseppe, P.; Simon, C.; Wassim, A.; Angel, A. A. J.; Gedske, D.; Karim, F.; Eliahu, G.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Potential impact of avelumab + axitinib (A + Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach

Meeting Abstract

Zheng, J.; Chang, A.; Larkin, J.; Motzer, R. J.; Amantea, M.; Bello, C.; Pavlov, D.; Geraldes, M.; Martignoni, M.; Di Pietro, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update

Meeting Abstract

Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, M. W.; Autio, K.; Infante, J. R.; Patel, M. R.; Papadopoulos, K.; Naing, A.; Gabrail, N.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

Meeting Abstract

Staehler, M.; Motzer, R. J.; George, D. J.; Pandha, H. S.; Donskov, F.; Escudier, B.; Kliment, J.; Pantuck, A. J.; Patel, A.; Deannuntis, L.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes

Meeting Abstract

Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)

Meeting Abstract

Petrylak, D.; Vogelzang, N. J.; Fradet, Y.; Bajorin, D.; de Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Climent, M. A.; Necchi, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)